Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

(OP: SDZXF )

45.05 UNCHANGED
Last Price Updated: 12:10 PM EST, Nov 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SDZXF

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. 
Via Benzinga
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M
Sandoz US, settles Generic Pharmaceuticals Pricing Antitrust Litigation for $265 million, addressing claims from direct purchasers without admitting wrongdoing. Post-approval, litigation continues with... 
Via Benzinga
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs. 
Via Benzinga
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC:  
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.